The vaccine, known as antisera, was tested in combination with Merck's established immunotherapy drug Keytruda ...

This drug is helping reduce the risk of the cancer returning or spreading compared with Merck's immunotherapy drug Keytruda ...

A study of high-risk melanoma patients, the companies said the experimental treatment using two drugs in combination ...

On Wednesday, the Treasury Department's decision to double its purchases of longer-dated bonds sent yields lower and gave stocks some breathing room.

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

Moderna and Merck developed a treatment they say has the ability to prevent the reoccurrence of the deadliest form of skin center.

An experimental mRNA-based vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients, Moderna and its partner Merck said Wednesday, paving the way ...

Ahead of US stock trading that day, Moderna and Merck jointly announced the results of the Phase III INTerpath-001 clinical ...

Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of ...

It’s very exciting,” a melanoma expert said of the experimental cancer vaccine announced by pharmaceutical companies Moderna ...